PharmacologyNews.net

Pharmacology Xagena

Venous thromboembolism ( VTE ), comprising deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ), is a common, potentially lethal condition with acute morbidity. Researchers have reviewed the ...


The treatment of drug sensitive strains of tuberculosis ( TB ) requires minimum duration of 6 months. However, for multiple drug-resistant tuberculosis ( MDR-TB ) and extensive drug-resistance tubercu ...


The Food and Drug Administration ( FDA ) has approved Mekinist ( Trametinib ) for use in combination with Tafinlar ( Dabrafenib ) for the treatment of patients with unresectable melanoma ( melanoma th ...


Whereas vaccines are designed to stimulate tumor antigen-specific immune responses, immune checkpoint inhibitors, in theory, should remove the brakes on most T-cell-mediated immune responses. This mec ...


The challenge of new therapeutic agents and combinations is to improve virological response, shorten the length of therapy and offer treatment free of Interferon. New treatments will need to be evalua ...


The approval of two hepatitis C virus ( HCV ) protease inhibitors by the FDA ( Food and Drug Administration ) in 2011, Boceprevir ( Victrelis ) and Telaprevir ( Incivo, Incivek ), marked the start of ...


A variety of pharmacologic agents are available for the treatment of neurogenic bladder ( NGB ) as part of a patient’s comprehensive bladder management program. The most commonly used class of med ...


Improved understanding of HCV replication has allowed for the development of new therapeutic agents that target enzymes directly. HCV is a flavivirus with an RNA genome encoding a polyprotein. After H ...


Immunotherapy of cancer has a history full of important discoveries that goes back to the late nineteenth century, when William B. Coley observed tumor regressions following the injection of a bacteri ...


Rivaroxaban ( Xarelto ) is indicated for the treatment of deep vein thrombosis ( DVT ), and prevention of recurrent DVT and pulmonary embolism ( PE ) following an acute deep vein thrombosis in adults. ...


A study has evaluated a novel PEGylated form of Interferon beta-1a ( PEG-IFN beta-1a; Plegridy ), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. Two rand ...


Cancer patients treated with Bevacizumab ( Avastin ) in combination with chemotherapy are at significantly greater risk of potentially life-threatening gastrointestinal perforations, particularly pa ...


Two review studies evaluating the safety of the selective cyclooxygenase 2 ( COX-2 ) inhibitors and non-steroidal anti-inflammatory drugs ( NSAIDs ) have found increased cardiovascular and kidney risk ...


Clinical trials comparing antithrombotic therapy with placebo have shown that Warfarin ( Coumadin ) reduces the risk of stroke by 62%, and that Acetylsalicylic acid ( ASA, Aspirin ) alone reduces the ...


Studying mice, researchers at Washington University School of Medicine in St. Louis have identified two key components in the pain cascade that may provide targets for more effective analgesic drugs w ...


Researchers, at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy, found that 29 percent of patients seen at local primary-care offices had taken at least one ...


One in five patients taking diuretics commonly prescribed for high blood pressure or heart conditions end up with reduced sodium and potassium levels. Recent evidence suggests that perhaps as few a ...


Researchers, at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy, found that 29 percent of patients seen at local primary-care offices had taken at least one ...


One in five patients taking diuretics commonly prescribed for high blood pressure or heart conditions end up with reduced sodium and potassium levels. Recent evidence suggests that perhaps as few a ...


Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models. The findings o ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati